REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ...
Please provide your email address to receive an email when new articles are posted on . AUSTIN, Texas — Real-world dose escalation of Stelara was safe and effective in patients with perianal Crohn’s ...
The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April ...
The product is expected to be available in the first half of 2025. The Food and Drug Administration (FDA) has approved Imuldosa ™ (ustekinumab-srlf), a biosimilar to Stelara ® (ustekinumab), for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results